Cardiac Myosin Binding Protein C Phosphorylation is Cardioprotective

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2006 Nov 1

PMID 17075052

Citations 140

Authors

Sakthivel Sadayappan

Hanna Osinska

Raisa Klevitsky

John N Lorenz

Michelle Sargent

Jeffrey D Molkentin

Christine E Seidman

Jonathan G Seidman

Jeffrey Robbins

Affiliations

Soon will be listed here.

Abstract

Cardiac myosin binding protein C (cMyBP-C) has three phosphorylatable serines at its N terminus (Ser-273, Ser-282, and Ser-302), and the residues' phosphorylation states may alter thick filament structure and function. To examine the effects of cMyBP-C phosphorylation, we generated transgenic mice with cardiac-specific expression of a cMyBP-C in which the three phosphorylation sites were mutated to aspartic acid, mimicking constitutive phosphorylation (cMyBP-C(AllP+)). The allele was bred into a cMyBP-C null background (cMyBP-C((t/t))) to ensure the absence of endogenous dephosphorylated cMyBP-C. cMyBP-C(AllP+) was incorporated normally into the cardiac sarcomere and restored normal cardiac function in the null background. However, subtle changes in sarcomere ultrastructure, characterized by increased distances between the thick filaments, indicated that phosphomimetic cMyBP-C affects thick-thin filament relationships, and yeast two-hybrid data and pull-down studies both showed that charged residues in these positions effectively prevented interaction with the myosin heavy chain. Confirming the physiological relevance of these data, the cMyBP-C(AllP+:(t/t)) hearts were resistant to ischemia-reperfusion injury. These data demonstrate that cMyBP-C phosphorylation functions in maintaining thick filament spacing and structure and can help protect the myocardium from ischemic injury.

Citing Articles

Myocardial overexpression of protein phosphatase 2A-B56α improves resistance against ischemia-reperfusion injury.

Herting J, Berg A, Hadova K, Heinick A, Konig S, Kuhlmann M J Mol Cell Cardiol Plus. 2025; 3():100030.

PMID: 39803363 PMC: 11708487. DOI: 10.1016/j.jmccpl.2022.100030.

D389V Variant Induces Hypercontractility in Cardiac Organoids.

Desai D, Song T, Singh R, Baby A, McNamara J, Green L Cells. 2024; 13(22).

PMID: 39594661 PMC: 11592734. DOI: 10.3390/cells13221913.

Cardiac myosin binding protein-C phosphorylation as a function of multiple protein kinase and phosphatase activities.

Kampourakis T, Ponnam S, Campbell K, Wellette-Hunsucker A, Koch D Nat Commun. 2024; 15(1):5111.

PMID: 38877002 PMC: 11178824. DOI: 10.1038/s41467-024-49408-5.

Hypertrophic cardiomyopathy in carriers in aging.

Ananthamohan K, Stelzer J, Sadayappan S J Cardiovasc Aging. 2024; 4(1.

PMID: 38406555 PMC: 10883298. DOI: 10.20517/jca.2023.29.

Cardiac myosin-binding protein C N-terminal interactions with myosin and actin filaments: Opposite effects of phosphorylation and M-domain mutations.

Wong F, Bunch T, Lepak V, Steedman A, Colson B J Mol Cell Cardiol. 2023; 186:125-137.

PMID: 38008210 PMC: 10872421. DOI: 10.1016/j.yjmcc.2023.11.010.

References

McConnell B, Jones K, Fatkin D, Arroyo L, Lee R, Aristizabal O . Dilated cardiomyopathy in homozygous myosin-binding protein-C mutant mice. J Clin Invest. 1999; 104(9):1235-44. PMC: 409819. DOI: 10.1172/JCI7377. View

Herron T, Rostkova E, Kunst G, Chaturvedi R, Gautel M, Kentish J . Activation of myocardial contraction by the N-terminal domains of myosin binding protein-C. Circ Res. 2006; 98(10):1290-8. DOI: 10.1161/01.RES.0000222059.54917.ef. View

Levine R, WEISBERG A, Kulikovskaya I, McClellan G, Winegrad S . Multiple structures of thick filaments in resting cardiac muscle and their influence on cross-bridge interactions. Biophys J. 2001; 81(2):1070-82. PMC: 1301576. DOI: 10.1016/S0006-3495(01)75764-5. View

McClellan G, Kulikovskaya I, Winegrad S . Changes in cardiac contractility related to calcium-mediated changes in phosphorylation of myosin-binding protein C. Biophys J. 2001; 81(2):1083-92. PMC: 1301577. DOI: 10.1016/S0006-3495(01)75765-7. View

Frances C, Nazeyrollas P, Prevost A, Moreau F, Pisani J, Davani S . Role of beta 1- and beta 2-adrenoceptor subtypes in preconditioning against myocardial dysfunction after ischemia and reperfusion. J Cardiovasc Pharmacol. 2003; 41(3):396-405. DOI: 10.1097/00005344-200303000-00008. View

Kulikovskaya I, McClellan G, Flavigny J, Carrier L, Winegrad S . Effect of MyBP-C binding to actin on contractility in heart muscle. J Gen Physiol. 2003; 122(6):761-74. PMC: 2229591. DOI: 10.1085/jgp.200308941. View

Kaiser R, Bueno O, Lips D, Doevendans P, Jones F, Kimball T . Targeted inhibition of p38 mitogen-activated protein kinase antagonizes cardiac injury and cell death following ischemia-reperfusion in vivo. J Biol Chem. 2004; 279(15):15524-30. DOI: 10.1074/jbc.M313717200. View

Oakley C, Hambly B, Curmi P, Brown L . Myosin binding protein C: structural abnormalities in familial hypertrophic cardiomyopathy. Cell Res. 2004; 14(2):95-110. DOI: 10.1038/sj.cr.7290208. View

Offer G, Moos C, Starr R . A new protein of the thick filaments of vertebrate skeletal myofibrils. Extractions, purification and characterization. J Mol Biol. 1973; 74(4):653-76. DOI: 10.1016/0022-2836(73)90055-7. View

10.

Moos C, Mason C, Besterman J, Feng I, Dubin J . The binding of skeletal muscle C-protein to F-actin, and its relation to the interaction of actin with myosin subfragment-1. J Mol Biol. 1978; 124(4):571-86. DOI: 10.1016/0022-2836(78)90172-9. View

11.

Mercadier J, Lompre A, Wisnewsky C, Samuel J, Bercovici J, Swynghedauw B . Myosin isoenzyme changes in several models of rat cardiac hypertrophy. Circ Res. 1981; 49(2):525-32. DOI: 10.1161/01.res.49.2.525. View

12.

Bahler M, Moser H, Eppenberger H, Wallimann T . Heart C-protein is transiently expressed during skeletal muscle development in the embryo, but persists in cultured myogenic cells. Dev Biol. 1985; 112(2):345-52. DOI: 10.1016/0012-1606(85)90405-1. View

13.

Kawashima M, Kitani S, Tanaka T, Obinata T . The earliest form of C-protein expressed during striated muscle development is immunologically the same as cardiac-type C-protein. J Biochem. 1986; 99(4):1037-47. DOI: 10.1093/oxfordjournals.jbchem.a135567. View

14.

Garvey J, Kranias E, Solaro R . Phosphorylation of C-protein, troponin I and phospholamban in isolated rabbit hearts. Biochem J. 1988; 249(3):709-14. PMC: 1148764. DOI: 10.1042/bj2490709. View

15.

Gautel M, Zuffardi O, Freiburg A, Labeit S . Phosphorylation switches specific for the cardiac isoform of myosin binding protein-C: a modulator of cardiac contraction?. EMBO J. 1995; 14(9):1952-60. PMC: 398294. DOI: 10.1002/j.1460-2075.1995.tb07187.x. View

16.

Di Lisa F, De Tullio R, Salamino F, Barbato R, Melloni E, SILIPRANDI N . Specific degradation of troponin T and I by mu-calpain and its modulation by substrate phosphorylation. Biochem J. 1995; 308 ( Pt 1):57-61. PMC: 1136842. DOI: 10.1042/bj3080057. View

17.

Freiburg A, Gautel M . A molecular map of the interactions between titin and myosin-binding protein C. Implications for sarcomeric assembly in familial hypertrophic cardiomyopathy. Eur J Biochem. 1996; 235(1-2):317-23. DOI: 10.1111/j.1432-1033.1996.00317.x. View

18.

WEISBERG A, Winegrad S . Alteration of myosin cross bridges by phosphorylation of myosin-binding protein C in cardiac muscle. Proc Natl Acad Sci U S A. 1996; 93(17):8999-9003. PMC: 38584. DOI: 10.1073/pnas.93.17.8999. View

19.

Spirito P, Seidman C, McKenna W, Maron B . The management of hypertrophic cardiomyopathy. N Engl J Med. 1997; 336(11):775-85. DOI: 10.1056/NEJM199703133361107. View

20.

Van Eyk J, Powers F, Law W, Larue C, Hodges R, Solaro R . Breakdown and release of myofilament proteins during ischemia and ischemia/reperfusion in rat hearts: identification of degradation products and effects on the pCa-force relation. Circ Res. 1998; 82(2):261-71. DOI: 10.1161/01.res.82.2.261. View